SGMO Stock Overview
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sangamo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$1.78 |
| 52 Week Low | US$0.29 |
| Beta | 1.35 |
| 1 Month Change | -37.00% |
| 3 Month Change | 12.27% |
| 1 Year Change | -70.24% |
| 3 Year Change | -95.91% |
| 5 Year Change | -95.91% |
| Change since IPO | -96.78% |
Recent News & Updates
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16Recent updates
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Jan 10Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December
Dec 03We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow
Sep 22Sangamo Therapeutics: Finding An Opportunity To Reload
Aug 21Sangamo's Hemophilia A Treatment: An Assessment
May 31We Think Some Shareholders May Hesitate To Increase Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation
May 19Sangamo Therapeutics Q1 2021 Earnings Preview
May 03Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27What Type Of Shareholders Own The Most Number of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares?
Feb 12
Bearish: Analysts Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue and EPS estimates
Jan 08Shareholder Returns
| SGMO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | -4.7% | -3.7% |
| 1Y | -70.2% | -2.7% | 20.2% |
Return vs Industry: SGMO underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: SGMO underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SGMO volatility | |
|---|---|
| SGMO Average Weekly Movement | 25.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGMO's share price has been volatile over the past 3 months.
Volatility Over Time: SGMO's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 405 | Sandy Macrae | www.sangamo.com |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. Fundamentals Summary
| SGMO fundamental statistics | |
|---|---|
| Market cap | US$98.80m |
| Earnings (TTM) | -US$257.83m |
| Revenue (TTM) | US$176.23m |
0.6x
P/S Ratio-0.4x
P/E RatioIs SGMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGMO income statement (TTM) | |
|---|---|
| Revenue | US$176.23m |
| Cost of Revenue | US$221.56m |
| Gross Profit | -US$45.32m |
| Other Expenses | US$212.51m |
| Earnings | -US$257.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | -25.72% |
| Net Profit Margin | -146.30% |
| Debt/Equity Ratio | 0% |
How did SGMO perform over the long term?
See historical performance and comparison